Gan & Lee Pharmaceuticals Management
Management criteria checks 4/4
Gan & Lee Pharmaceuticals' CEO is Kai Du, appointed in Jul 2020, has a tenure of 4.83 years. directly owns 0.087% of the company’s shares, worth CN¥26.56M. The average tenure of the management team and the board of directors is 4.8 years and 5.1 years respectively.
Key information
Kai Du
Chief executive officer
CN¥1.0m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4.8yrs |
| CEO ownership | 0.09% |
| Management average tenure | 4.8yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
CEO
Kai Du (47 yo)
Mr. Kai Du is General Manager of Gan & Lee Pharmaceuticals. since July 20, 2020 and has been its Director since April 26, 2019.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 27.3yrs | CN¥457.20k | 30.61% CN¥ 9.4b | |
| GM & Director | 4.8yrs | CN¥1.04m | 0.087% CN¥ 26.6m | |
| CFO & Deputy GM | 4.8yrs | CN¥695.20k | 0.089% CN¥ 27.1m | |
| Deputy GM & Director | 1.3yrs | CN¥892.20k | 0.087% CN¥ 26.6m | |
| Deputy GM & Director | 9.3yrs | CN¥960.50k | 0.087% CN¥ 26.6m | |
| Secretary | 7.4yrs | CN¥695.00k | 0.087% CN¥ 26.6m | |
| Deputy General Manager | 4.8yrs | CN¥752.80k | 0.087% CN¥ 26.6m | |
| Deputy General Manager | 4.8yrs | CN¥710.50k | 0.087% CN¥ 26.6m | |
| Deputy General Manager | 1.3yrs | no data | no data | |
| Head of Accounting | no data | no data | no data | |
| Head of Administrative Department & Supervisor | no data | no data | no data | |
| Supervisor & Archives Manager | no data | no data | no data |
Experienced Management: 603087's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 27.3yrs | CN¥457.20k | 30.61% CN¥ 9.4b | |
| GM & Director | 6.1yrs | CN¥1.04m | 0.087% CN¥ 26.6m | |
| Deputy GM & Director | 3.7yrs | CN¥892.20k | 0.087% CN¥ 26.6m | |
| Deputy GM & Director | 9.7yrs | CN¥960.50k | 0.087% CN¥ 26.6m | |
| Head of Administrative Department & Supervisor | less than a year | no data | no data | |
| Supervisor & Archives Manager | 6.1yrs | no data | no data | |
| Director | 4.2yrs | CN¥1.04m | 0.045% CN¥ 13.8m | |
| Independent Director | 6.1yrs | CN¥72.00k | no data | |
| Independent Director | 6.1yrs | CN¥72.00k | no data | |
| Supervisor | 4.2yrs | no data | no data | |
| Independent Director | 3yrs | CN¥72.00k | no data | |
| Chairman of the Supervisory Board | less than a year | no data | no data |
Experienced Board: 603087's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 02:00 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gan & Lee Pharmaceuticals. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhu Chen | Citic Securities Co., Ltd. |
| Shitong Han | Citic Securities Co., Ltd. |
| Tianyi Yan | Goldman Sachs |